Costs of treating multidrug-resistant TB in California in 2022.
作者信息
Katrak S, Wang R, Barry P
机构信息
Tuberculosis Control Branch, California Department of Public Health, Richmond, CA, Division of Infectious Diseases, University of California, San Francisco, CA, USA.
Tuberculosis Control Branch, California Department of Public Health, Richmond, CA.
出版信息
Int J Tuberc Lung Dis. 2023 Nov 1;27(11):864-866. doi: 10.5588/ijtld.23.0150.
Abstract
摘要
相似文献
1
Costs of treating multidrug-resistant TB in California in 2022.2022年加利福尼亚州治疗耐多药结核病的费用。
Int J Tuberc Lung Dis. 2023 Nov 1;27(11):864-866. doi: 10.5588/ijtld.23.0150.
2
Multidrug resistance among persons with tuberculosis in California, 1994-2003.1994 - 2003年加利福尼亚州结核病患者中的多重耐药情况。
JAMA. 2005 Jun 8;293(22):2732-9. doi: 10.1001/jama.293.22.2732.
3
Estimated treatment costs for multidrug-resistant TB in the United States.美国耐多药结核病的估计治疗费用。
Int J Tuberc Lung Dis. 2024 Apr 1;28(4):214-215. doi: 10.5588/ijtld.23.0621.
4
First Case of Multidrug Resistant Spinal TB in Ireland.爱尔兰首例耐多药脊柱结核病例。
Ir Med J. 2016 Oct 12;109(9):473.
5
Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.俄罗斯弗拉基米尔地区原发性耐多药结核病的流行病学
Emerg Infect Dis. 2015 Nov;21(11):2048-51. doi: 10.3201/eid2111.150813.
6
Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?朝鲜的耐多药结核病治疗：扩大规模是否可行？
PLoS Med. 2016 Aug 2;13(8):e1002062. doi: 10.1371/journal.pmed.1002062. eCollection 2016 Aug.
7
[Chemotherapy of tuberculosis and its challenges].[结核病的化学疗法及其挑战]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Aug;31(4):389-92.
8
Extensive drug-resistant TB: a threat for Europe?广泛耐药结核病：对欧洲构成威胁？
Euro Surveill. 2006 Sep 28;11(9):E060928.2. doi: 10.2807/esw.11.39.03056-en.
9
Multidrug-resistant tuberculosis in Ukraine at a time of military conflict.乌克兰军事冲突时期的耐多药结核病
Int J Tuberc Lung Dis. 2015 Apr;19(4):492-3. doi: 10.5588/ijtld.14.0940.
10
Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.世卫组织称，耐多药结核病：全口服治疗方案应有助于提高依从性。
BMJ. 2018 Aug 21;362:k3610. doi: 10.1136/bmj.k3610.
引用本文的文献
1
The fall of the mycobacterial cell wall: interrogating peptidoglycan synthesis for novel anti-TB agents.分枝杆菌细胞壁的瓦解：针对新型抗结核药物对肽聚糖合成的探索。
PeerJ. 2024 Nov 14;12:e18404. doi: 10.7717/peerj.18404. eCollection 2024.
本文引用的文献
1
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.24 周全口服方案治疗利福平耐药结核病。
N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166.
2
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.从支付者角度看美国直接作用抗病毒药物治疗慢性丙型肝炎病毒的成本效益。
J Manag Care Spec Pharm. 2022 Oct;28(10):1138-1148. doi: 10.18553/jmcp.2022.28.10.1138.
3
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.贝达喹啉、普托马尼德和利奈唑胺治疗南非、格鲁吉亚和菲律宾广泛耐药结核病的成本效益。
BMJ Open. 2021 Dec 3;11(12):e051521. doi: 10.1136/bmjopen-2021-051521.
4
Cost of multidrug resistant tuberculosis in Germany-An update.德国耐多药结核病的成本：更新。
Int J Infect Dis. 2021 Feb;103:102-109. doi: 10.1016/j.ijid.2020.10.084. Epub 2020 Nov 3.
5
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.耐多药肺结核的治疗。
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
6
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
7
The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs.加利福尼亚多重耐药结核病咨询服务：州与地方项目的合作关系。
Public Health Action. 2018 Mar 21;8(1):7-13. doi: 10.5588/pha.17.0091.
8
Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.估算过去二十年美国结核病病例及其避免的经济成本。
Int J Tuberc Lung Dis. 2016 Jul;20(7):926-33. doi: 10.5588/ijtld.15.1001.
9
Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.2005 - 2007年美国耐多药和广泛耐药结核病的治疗方法、治疗结果及费用
Emerg Infect Dis. 2014 May;20(5):812-21. doi: 10.3201/eid2005.131037.
10
Determining the cost of tuberculosis case management in a low-incidence state.确定低发病率州结核病病例管理的成本。
Int J Tuberc Lung Dis. 2008 Mar;12(3):301-7.
Zotero 插件